Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial - Quiz - MDSpire

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

  • By

  • Louis J. Aronne

  • Deborah B. Horn

  • Carel W. le Roux

  • Ariana M. Chao

  • Wayne Ho

  • Bruno Halpern

  • Ryan Griffin

  • Cathy Xie

  • Elisa Gomez Valderas

  • Clare J. Lee

  • Anderson Ribeiro

  • David M. Hyman

  • Leonard Glass

  • Neena Xavier

  • May 13, 2026

  • 0 min

Share

Original Source(s)

Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial

  • by Louis J. Aronne, Deborah B. Horn, Carel W. le Roux, Ariana M. Chao, Wayne Ho, Bruno Halpern, Ryan Griffin, Cathy Xie, Elisa Gomez Valderas, Clare J. Lee, Anderson Ribeiro, David M. Hyman, Leonard Glass, Neena Xavier

  • May 13, 2026

Related Content

Lipidomics Point to Obesity–Alzheimer's Link

Study uses multi-omics tools to examine obesity-related pathways linked to neurodegeneration

  • May 26, 2026

  • 2 min
Retatrutide Shows 28% Weight Loss in Phase 3 Trial

Nearly half of participants receiving the highest dose achieved at least 30% body weight reduction.

Epicardial fat area as an independent predictor of atrial fibrillation occurrence and severity